Omega-3 fatty acids may slow down early Alzheimer´s in some cases
Several studies have shown that eating fish, which is high in omega-3 fatty acids, may protect against Alzheimer´s disease, leading researchers to question whether supplements could have similar effects. Dr Yvonne Freund-Levi and colleagues at KI in Stockholm and Uppsala University in Uppsala, Sweden, compared the effects of supplements containing two omega-3 fatty acids with placebo in 204 patients with Alzheimer´s disease, by which 174 completed the entire study. For six months, 89 patients (51 women and 38 men) took 1.7 grams of docosahexaenoic acid (DHA) and .6 grams of eicosapentaenoic acid (EPA), while 85 patients (39 women and 46 men) took placebo. For an additional six months, both groups took the omega-3 fatty acids. Patients had physical examinations, which included blood tests and blood pressure measurement, and took cognitive tests at the beginning of the study and at the six- and 12-month marks.
After six months, there was no difference in the rate of cognitive decline between the two groups. However, among a subgroup of 32 patients with very mild cognitive impairment at the beginning of the study, those who took the fatty acids experienced less decline in six months compared with those who took placebo. Among those who took placebo during the first six months, decline decreased during the second six months, when they also began taking the omega-3 supplements. The supplements appeared safe and well-tolerated, with no change in blood pressure or blood test results other than a higher ratio of fatty acids in the blood.
"These findings cannot serve as a basis for general recommendations for treatment of Alzheimer´s disease with dietary DHA-rich fish oil preparations", says professor Jan Palmblad. "Studies in larger cohorts with mild cognitive impairment, including those at risk for Alzheimer´s disease, are needed to further explore the possibility that omega-3 fatty acids might be beneficial in halting initial progression of the disease." Publication:
Original publication: Y. F. Levi, M. Eriksdotter-Jönhagen, T. Cederholm, H. Basun, G. F. Irving, A. Garlind, I. Vedin, B. Vessby, L.-O. Wahlund, J. Palmblad; "Omega-3 fatty acid treatment of 174 patients with mild to moderate Alzheimer´s disease (OmegAD): a randomized double-blind trial"; Archives of Neurology 2006; 63:1402-1408.
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.